Compositions providing for increased IGF-I solubility

Details Compositions providing for increased IGF-I solubility Compositions providing for increased IGF-I solubility

2007-08-28

2007-08-28

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S634000, C530S300000, C530S324000, C530S303000, C530S399000

Reexamination Certificate

active

11230105

ABSTRACT:
Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures.

REFERENCES:
patent: 4769361 (1988-09-01), Burleigh et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5231178 (1993-07-01), Holtz et al.
patent: 5352452 (1994-10-01), Kohnert et al.
patent: 5410026 (1995-04-01), Chang et al.
patent: 5597897 (1997-01-01), Ron et al.
patent: 5681814 (1997-10-01), Clark et al.
patent: 6767892 (2004-07-01), Shirley et al.
patent: 0 217 379 (1987-04-01), None
patent: WO92/04363 (1992-03-01), None
patent: WO94/15584 (1994-07-01), None
Fransson, et al., “Local Tolerance of Subcutaneous Injections”Journal of Pharm. Pharmacol. (1996) pp. 1012-1015, vol. 48.
The Merck Index, 12thed., Merck & Co., Inc., Whitehouse Station, NJ, 1996, p. 7724.

Affiliated with

Also associated with

Rating

Compositions providing for increased IGF-I solubility does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions providing for increased IGF-I solubility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions providing for increased IGF-I solubility will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3826919